ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: They also had similar early molecular responses defined as BCR‐ABL PCR less than 10% at 3 months to those who receive original imatinib in the upfront setting, which correlates with better event‐free survival.33, 34 In Algeria, Entasoltan et al retrospectively reviewed 355 patients newly diagnosed with CML and treated with upfront generic imatinib (CIPLA Imatib, India).